CG Oncology CGON Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about CG Oncology's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CG Oncology's additional paid-in capital?
- CG Oncology (CGON) reported additional paid-in capital of $1.53B in Q1 2026.
- How has CG Oncology's additional paid-in capital changed year-over-year?
- CG Oncology's additional paid-in capital increased by 59.9% year-over-year, from $957.18M to $1.53B.
- What is the long-term trend for CG Oncology's additional paid-in capital?
- Over 2 years (2023 to 2025), CG Oncology's additional paid-in capital has grown at a 1186.0% compound annual growth rate (CAGR), from $6.84M to $1.13B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.